Talphera (TLPH) Liabilities from Discontinued Operations (2022 - 2026)
Talphera (TLPH) posted Liabilities from Discontinued Operations of $650000.0 for Q2 2026, little changed on a QoQ basis from $650000.0 in Q1 2026, and little changed year-over-year from $650000.0 in Q2 2025.
Analysis
Talphera (TLPH) Liabilities from Discontinued Operations (2022 - 2026) Analysis & Trends
Talphera has reported Liabilities from Discontinued Operations for 5 years, with the latest figure at $650000.0 in Q2 2026.
- On a quarterly basis, Liabilities from Discontinued Operations changed 0.0% year-over-year to $650000.0 in Q2 2026; TTM through Jun 2026 was $650000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $650000.0, down 10.1% from the prior year.
- Liabilities from Discontinued Operations was $650000.0 for Q2 2026 at Talphera, roughly flat from $650000.0 in the prior quarter.
- The five-year high for Liabilities from Discontinued Operations was $4.6 million in Q4 2022, with the low at $650000.0 in Q1 2025.
- Average Liabilities from Discontinued Operations over 5 years is $1.2 million, with a median of $723000.0 recorded in 2024.
- The sharpest annual moves came in 2023 and 2026: Liabilities from Discontinued Operations tumbled 84.18% in 2023, then changed 0.0% in 2026.
- Over 5 years, Liabilities from Discontinued Operations stood at $4.6 million in 2022, then sank by 84.18% to $731000.0 in 2023, then declined by 1.09% to $723000.0 in 2024, then fell by 10.1% to $650000.0 in 2025, then changed by 0.0% to $650000.0 in 2026.
- The last three Liabilities from Discontinued Operations figures came in at $650000.0 (Q2 2026), $650000.0 (Q1 2026), and $650000.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn |
| 10 | Talphera | 92.90 Mn | 92.90 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 650,000.00 |
| Mar 31, 2026 | 650,000.00 |
| Dec 31, 2025 | 650,000.00 |
| Sep 30, 2025 | 650,000.00 |
| Jun 30, 2025 | 650,000.00 |
| Mar 31, 2025 | 650,000.00 |
| Dec 31, 2024 | 723,000.00 |
| Sep 30, 2024 | 723,000.00 |
| Jun 30, 2024 | 723,000.00 |
| Mar 31, 2024 | 730,000.00 |
| Dec 31, 2023 | 731,000.00 |
| Sep 30, 2023 | 756,000.00 |
| Jun 30, 2023 | 1.16 Mn |
| Mar 31, 2023 | 3.28 Mn |
| Dec 31, 2022 | 4.62 Mn |